Authors’ reply
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d3347 (Published 31 May 2011) Cite this as: BMJ 2011;342:d3347
- Susan Jick, director1,
- Lianne Parkin, senior lecturer in epidemiology2,
- Rohini Hernandez, epidemiologist1,
- Katrina Sharples, senior lecturer in biostatistics2
- 1Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
- 2Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
- sjick{at}bu.edu
Shapiro’s suggestion that the rates of venous thromboembolism (VTE) in our studies are egregiously low is unfounded.1 The incidence rates for levonorgestrel users in our study agree with those found in earlier studies of idiopathic VTE in women of childbearing age (including a large World Health Organization hospital based study that prospectively ascertained cases), and the estimates for drospirenone are similar to those found for third generation oral contraceptives.2 3 The incidence rate quoted by Shapiro, which came from a consensus statement from a workshop convened by the manufacturers of drospirenone, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.